Molecular Subtypes and Biomarker-based Detection of Breast Cancer: Challenges and Future Perspectives
DOI:
https://doi.org/10.56919/usci.2541.022Keywords:
Breast cancer, Molecular subtypes, Screening, Treatment, SurvivorshipAbstract
Study’s Excerpt:
• It is crucial to prioritize early detection through affordable screening and awareness initiatives, especially in environments with limited resources.
• The integration of novel imaging techniques, genetic testing, artificial intelligence, and multidisciplinary approaches has revolutionized breast cancer management.
• High calorie consumption leads to weight gain and ultimately obesity, which is linked to an increased cancer risk.
Full Abstract:
Breast cancer remains a serious global health challenge, being the leading cause of cancer-related death in women. Its prevalence is still rising despite improvements in diagnostic techniques and awareness efforts. However, disparity exists due to its complex molecular heterogeneity and limited access to advanced diagnostics. Genetic and epigenetic changes such as DNA methylation, histone modification, non-coding RNAs, alterations in tumor suppressor genes, immune system interactions, and hormonal and growth factor signaling pathways contribute to breast cancer pathogenesis. Racial discrimination and socioeconomic determinants of health can also affect prognosis, even though biological differences by ethnicity may be partially responsible for the observed discrepancies. This review highlights the continued challenges and opportunities in enhancing the prognosis of breast cancer worldwide, in addition to bringing into light the molecular mechanisms, molecular subtypes, and innovative approaches to early detection and treatment of breast cancer.
References
Abd El-Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J., Blamey, R. W., Robertson, J. F. R., Nicholson, R. I., & Ellis, I. O. (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. The Journal of Pathology, 203(2), 661–671. https://doi.org/10.1002/path.1559
Agurs-Collins, T., Ross, S. A., & Dunn, B. K. (2019). The many faces of obesity and its influence on breast cancer risk. Frontiers in Oncology, 9(September), 1–14. https://doi.org/10.3389/fonc.2019.00765
Allison, K. H. (2021). Prognostic and predictive parameters in breast pathology: A pathologist's primer. Modern Pathology, 34(Suppl 1), 94–106. https://doi.org/10.1038/s41379-020-00704-7
Anders, C., & Carey, L. A. (2008). Understanding and treating triple-negative breast cancer. Oncology (Williston Park, N.Y.), 22(11), 1233–1240, 1243.
Applebaum, M. A., Miller, B. T., Lopez, J., Doren, E. L., Laronga, C., & Smith, P. D. (2015). Change in body mass index after breast reconstruction and associated complications. Eplasty, 15, e43.
Aune, D., Chan, D. S. M., Greenwood, D. C., Vieira, A. R., Rosenblatt, D. A. N., Vieira, R., & Norat, T. (2012). Dietary fiber and breast cancer risk: A systematic review and meta-analysis of prospective studies. Annals of Oncology, 23(6), 1394–1402. https://doi.org/10.1093/annonc/mdr589
Azoulay, S., Laé, M., Fréneaux, P., Merle, S., Al Ghuzlan, A., Chnecker, C., Rosty, C., Klijanienko, J., Sigal-Zafrani, B., Salmon, R., Fourquet, A., Sastre-Garau, X., & Vincent-Salomon, A. (2005). KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Modern Pathology, 18(12), 1623–1631. https://doi.org/10.1038/modpathol.3800483
Barrios-Rodríguez, R., Toledo, E., Martinez-Gonzalez, M. A., Aguilera-Buenosvinos, I., Romanos-Nanclares, A., & Jiménez-Moleón, J. J. (2020). Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Recommendations and breast cancer in the SUN Project. Nutrients, 12(7). https://doi.org/10.3390/nu12072076
Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., Safari, E., & Farahmand, L. (2020). Breast cancer: Biology, biomarkers, and treatments. International Immunopharmacology, 84(April). https://doi.org/10.1016/j.intimp.2020.106535
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., Beck, J. T., Ito, Y., Yardley, D., Deleu, I., Perez, A., Bachelot, T., Vittori, L., Xu, Z., Mukhopadhyay, P., … Hortobagyi, G. N. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. The New England Journal of Medicine, 366(6), 520–529. https://doi.org/10.1056/NEJMoa1109653
Bates, J. P., Derakhshandeh, R., Jones, L., & Webb, T. J. (2018). Mechanisms of immune evasion in breast cancer. BMC Cancer, 18(1), 556. https://doi.org/10.1186/s12885-018-4441-3
Becker, L. M., O'Connell, J. T., Vo, A. P., Cain, M. P., Tampe, D., Bizarro, L., Sugimoto, H., McGow, A. K., Asara, J. M., Lovisa, S., McAndrews, K. M., Zielinski, R., Lorenzi, P. L., Zeisberg, M., Raza, S., LeBleu, V. S., & Kalluri, R. (2020). Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer. Cell Reports, 31(9), 107701. https://doi.org/10.1016/j.celrep.2020.107701
Bergholz, J. S., Wang, Q., Ramseier, M., Prakadan, S., Wang, W., Fang, R., Kabraji, S., Zhou, Q., Gray, G. K., Abell-Hart, K., Xie, S., Guo, X., Gu, H., Von, T., Jiang, T., Tang, S., Freeman, G. J., Kim, H.-J., … Zhao, J. J. (2023). PI3Kβ controls immune evasion in PTEN-deficient breast tumours. Nature, 617(7959), 139–146. https://doi.org/10.1038/s41586-023-05940-w
Boing, L., Vieira, M. de C. S., Moratelli, J., Bergmann, A., & Guimarães, A. C. de A. (2020). Effects of exercise on physical outcomes of breast cancer survivors receiving hormone therapy—A systematic review and meta-analysis. Maturitas, 141, 71–81. https://doi.org/10.1016/j.maturitas.2020.06.022
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 30(8), 1194–1220. https://doi.org/10.1093/annonc/mdz173
Carreira, H., Williams, R., Müller, M., Harewood, R., Stanway, S., & Bhaskaran, K. (2018). Associations between breast cancer survivorship and adverse mental health outcomes: A systematic review. Journal of the National Cancer Institute, 110(12), 1311–1327. https://doi.org/10.1093/jnci/djy177
Cheung, L. W. T., Yu, S., Zhang, D., Li, J., Ng, P. K. S., Panupinthu, N., Mitra, S., Ju, Z., Yu, Q., Liang, H., Hawke, D. H., Lu, Y., Broaddus, R. R., & Mills, G. B. (2014). Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell, 26(4), 479–494. https://doi.org/10.1016/j.ccell.2014.08.017
Cianfrocca, M., & Goldstein, L. J. (2004). Prognostic and predictive factors in early-stage breast cancer. The Oncologist, 9(6), 606–616. https://doi.org/10.1634/theoncologist.9-6-606
Cobleigh, M. A., Langmuir, V. K., Sledge, G. W., Miller, K. D., Haney, L., Novotny, W. F., Reimann, J. D., & Vassel, A. (2003). A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Seminars in Oncology, 30(5 Suppl 16), 117–124. https://doi.org/10.1053/j.seminoncol.2003.08.013
Coughlin, S. S., & Smith, S. A. (2015). The impact of the natural, social, built, and policy environments on breast cancer. Journal of Environment and Health Sciences, 1(3). https://doi.org/10.15436/2378-6841.15.020
Daniyal, A., Santoso, I., Gunawan, N. H. P., Barliana, M. I., & Abdulah, R. (2021). Genetic influences in breast cancer drug resistance. Breast Cancer (Dove Medical Press), 13, 59–85. https://doi.org/10.2147/BCTT.S284453
Dsouza, V. L., Adiga, D., Sriharikrishnaa, S., Suresh, P. S., Chatterjee, A., & Kabekkodu, S. P. (2021). Small nucleolar RNA and its potential role in breast cancer—A comprehensive review. Biochimica et Biophysica Acta. Reviews on Cancer, 1875(1), 188501. https://doi.org/10.1016/j.bbcan.2020.188501
El Masri, J., & Phadke, S. (2022). Breast cancer epidemiology and contemporary breast cancer care: A review of the literature and clinical applications. Clinical Obstetrics and Gynecology, 65(3), 461–481. https://doi.org/10.1097/GRF.0000000000000721
Fucito, A., Lucchetti, C., Giordano, A., & Romano, G. (2008). Genetic and epigenetic alterations in breast cancer: What are the perspectives for clinical practice? The International Journal of Biochemistry & Cell Biology, 40(4), 565–575. https://doi.org/10.1016/j.biocel.2007.10.018
Garrido-Sánchez, L., García-Fuentes, E., Fernández-García, D., Escoté, X., Alcaide, J., Perez-Martinez, P., Vendrell, J., & Tinahones, F. J. (2012). Zinc-alpha 2-glycoprotein gene expression in adipose tissue is related with insulin resistance and lipolytic genes in morbidly obese patients. PloS One, 7(3), e33264. https://doi.org/10.1371/journal.pone.0033264
Gerend, M. A., & Pai, M. (2008). Social determinants of Black-White disparities in breast cancer mortality: A review. Cancer Epidemiology, Biomarkers & Prevention, 17(11), 2913–2923. https://doi.org/10.1158/1055-9965.EPI-07-0633
Han, Y., Yu, X., Li, S., Tian, Y., & Liu, C. (2020). New perspectives for resistance to PARP inhibitors in triple-negative breast cancer. Frontiers in Oncology, 10, 578095. https://doi.org/10.3389/fonc.2020.578095
Hasenoehrl, T., Palma, S., Ramazanova, D., Kölbl, H., Dorner, T. E., Keilani, M., & Crevenna, R. (2020). Resistance exercise and breast cancer-related lymphedema—A systematic review update and meta-analysis. Supportive Care in Cancer, 28(8), 3593–3603. https://doi.org/10.1007/s00520-020-05521-x
Huang, S.-Y., Franc, B. L., Harnish, R. J., Liu, G., Mitra, D., Copeland, T. P., Arasu, V. A., Kornak, J., Jones, E. F., Behr, S. C., Hylton, N. M., Price, E. R., Esserman, L., & Seo, Y. (2018). Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis. NPJ Breast Cancer, 4, 24. https://doi.org/10.1038/s41523-018-0078-2
Iqbal, N., & Iqbal, N. (2014). Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Molecular Biology International, 2014, 852748. https://doi.org/10.1155/2014/852748
Johnson, A. R., Kimball, S., Epstein, S., Recht, A., Lin, S. J., Lee, B. T., James, T. A., & Singhal, D. (2019). Lymphedema incidence after axillary lymph node dissection: Quantifying the impact of radiation and the lymphatic microsurgical preventive healing approach. Annals of Plastic Surgery, 82(4S Suppl 3), S234–S241. https://doi.org/10.1097/SAP.0000000000001864
Joshi, S., Garlapati, C., & Aneja, R. (2022). Epigenetic determinants of racial disparity in breast cancer: Looking beyond genetic alterations. Cancers, 14(8). https://doi.org/10.3390/cancers14081903
Kabir, I. M., Idris, A. T., Abubakar, S. D., Isah, M. M., Usman, A., Yusuf, L., Bello, Z. M., & Mohammed, I. (2024). Immunohistochemistry as an indispensable tool in oncology. Indian Journal of Gynecologic Oncology, 22(3), 106. https://doi.org/10.1007/s40944-024-00875-0
Kalluri, R. (2016). The biology and function of exosomes in cancer. The Journal of Clinical Investigation, 126(4), 1208–1215. https://doi.org/10.1172/JCI81135
Karim, M. O., Khan, K. A., Khan, A. J., Javed, A., Fazid, S., & Aslam, M. I. (2020). Triple assessment of breast lump: Should we perform core biopsy for every patient? Cureus, 12(3), e7479. https://doi.org/10.7759/cureus.7479
Katsura, C., Ogunmwonyi, I., Saha, S., & Katsura, C. (2024). Doctors in training breast cancer: Presentation, investigation, and management. 4-10.
Kawiak, A. (2024). Molecular research and treatment of breast cancer 2.0. International Journal of Molecular Sciences, 25(7), 10–12. https://doi.org/10.3390/ijms25073932
Klingbeil, P., Natrajan, R., Everitt, G., Vatcheva, R., Marchio, C., Palacios, J., Buerger, H., Reis-Filho, J. S., & Isacke, C. M. (2010). CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Research and Treatment, 120(1), 95–109. https://doi.org/10.1007/s10549-009-0380-7
Kolak, A., Kamińska, M., Sygit, K., Budny, A., Surdyka, D., Kukiełka-Budny, B., & Burdan, F. (2017). Primary and secondary prevention of breast cancer. Annals of Agricultural and Environmental Medicine, 24(4), 549–553. https://doi.org/10.26444/aaem/75943
Kroemer, G., Senovilla, L., Galluzzi, L., André, F., & Zitvogel, L. (2015). Natural and therapy-induced immunosurveillance in breast cancer. Nature Medicine, 21(10), 1128–1138. https://doi.org/10.1038/nm.3944
Lahart, I. M., Metsios, G. S., Nevill, A. M., & Carmichael, A. R. (2015). Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies. Acta Oncologica, 54(5), 635–654. https://doi.org/10.3109/0284186X.2014.998275
LeBleu, V. S., & Neilson, E. G. (2020). Origin and functional heterogeneity of fibroblasts. FASEB Journal, 34(3), 3519–3536. https://doi.org/10.1096/fj.201903188R
Li, X., Hu, Y., & Aslanbeigi, F. (2025). Genetic and epigenetic alterations in night shift nurses with breast cancer: A narrative review. Cancer Cell International, 25(1), 20. https://doi.org/10.1186/s12935-025-03649-6
Lien, H. C., Hsiao, Y. H., Lin, Y. S., Yao, Y. T., Juan, H. F., Kuo, W. H., Hung, M. C., Chang, K. J., & Hsieh, F. J. (2007). Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: Identification of genes potentially related to epithelial-mesenchymal transition. Oncogene, 26(57), 7859–7871. https://doi.org/10.1038/sj.onc.1210593
Liu, Y., Nguyen, N., & Colditz, G. A. (2015). Links between alcohol consumption and breast cancer: A look at the evidence. Women's Health (London, England), 11(1), 65–77. https://doi.org/10.2217/whe.14.62
Lotter, W., Diab, A. R., Haslam, B., Kim, J. G., Grisot, G., Wu, E., Wu, K., Onieva, J. O., Boyer, Y., Boxerman, J. L., Wang, M., Bandler, M., Vijayaraghavan, G. R., & Sorensen, A. G. (2021). Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach. Nature Medicine, 27(2), 244–249. https://doi.org/10.1038/s41591-020-01174-9
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008). FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell, 132(6), 958–970. https://doi.org/10.1016/j.cell.2008.01.018
Manahan, E. R., Kuerer, H. M., Sebastian, M., Hughes, K. S., Boughey, J. C., Euhus, D. M., Boolbol, S. K., & Taylor, W. A. (2019). Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Annals of Surgical Oncology, 26(10), 3025–3031. https://doi.org/10.1245/s10434-019-07549-8
McCormack, V., McKenzie, F., Foerster, M., Zietsman, A., Galukande, M., Adisa, C., Anele, A., Parham, G., Pinder, L. F., Cubasch, H., Joffe, M., Beaney, T., Quaresma, M., Togawa, K., Abedi-Ardekani, B., Anderson, B. O., Schüz, J., & Dos-Santos-Silva, I. (2020). Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): A prospective cohort study. The Lancet Global Health, 8(9), e1203–e1212. https://doi.org/10.1016/S2214-109X(20)30261-8
Mittempergher, L., Delahaye, L. J., Witteveen, A. T., Snel, M. H., Mee, S., Chan, B. Y., Dreezen, C., Besseling, N., & Luiten, E. J. (2020). Performance characteristics of the BluePrint® breast cancer diagnostic test. Translational Oncology, 13(4), 100756. https://doi.org/10.1016/j.tranon.2020.100756
Monteran, L., & Erez, N. (2019). The dark side of fibroblasts: Cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Frontiers in Immunology, 10, 1835. https://doi.org/10.3389/fimmu.2019.01835
Mootz, A., Arjmandi, F., Dogan, B. E., & Evans, W. P. (2020). Health care disparities in breast cancer: The economics of access to screening, diagnosis, and treatment. Journal of Breast Imaging, 2(6), 524–529. https://doi.org/10.1093/jbi/wbaa093
NHS England Breast Cancer Advisory Group. (2016). Clinical guidelines for the management of breast cancer.
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018). Prognostic and predictive biomarkers in breast cancer: Past, present and future. Seminars in Cancer Biology, 52, 56–73. https://doi.org/10.1016/j.semcancer.2017.08.010
Orecchioni, S., Reggiani, F., Talarico, G., & Bertolini, F. (2015). Mechanisms of obesity in the development of breast cancer. Discovery Medicine, 20(109), 121–128.
Ovcaricek, T., Takac, I., & Matos, E. (2019). Multigene expression signatures in early hormone receptor-positive HER2-negative breast cancer. Radiology and Oncology, 53(3), 285–292. https://doi.org/10.2478/raon-2019-0038
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lønning, P. E., Børresen-Dale, A. L., Brown, P. O., & Botstein, D. (2000). Molecular portraits of human breast tumours. Nature, 406(6797), 747–752. https://doi.org/10.1038/35021093
Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M. (2015). Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast, 24, S26–S35. https://doi.org/10.1016/j.breast.2015.07.008
Pu, M., Messer, K., Davies, S. R., Vickery, T. L., Pittman, E., Parker, B. A., Ellis, M. J., Flatt, S. W., Marinac, C. R., Nelson, S. H., Mardis, E. R., Pierce, J. P., & Natarajan, L. (2020). Research-based PAM50 signature and long-term breast cancer survival. Breast Cancer Research and Treatment, 179(1), 197–206. https://doi.org/10.1007/s10549-019-05446-y
Rakha, E. A., El-Sayed, M. E., Menon, S., Green, A. R., Lee, A. H. S., & Ellis, I. O. (2008). Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Research and Treatment, 111(1), 121–127. https://doi.org/10.1007/s10549-007-9768-4
Reig, B., Heacock, L., Geras, K. J., & Moy, L. (2020). Machine learning in breast MRI. Journal of Magnetic Resonance Imaging, 52(4), 998–1018. https://doi.org/10.1002/jmri.26852
Richardson, L. C., Henley, S. J., Miller, J. W., Massetti, G., & Thomas, C. C. (2016). Patterns and trends in age-specific Black-White differences in breast cancer incidence and mortality—United States, 1999–2014. MMWR. Morbidity and Mortality Weekly Report, 65(40), 1093–1098. https://doi.org/10.15585/mmwr.mm6540a1
Romeo, V., Clauser, P., Rasul, S., Kapetas, P., Gibbs, P., Baltzer, P. A. T., Hacker, M., Woitek, R., Helbich, T. H., & Pinker, K. (2022). AI-enhanced simultaneous multiparametric (18)F-FDG PET/MRI for accurate breast cancer diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 49(2), 596–608. https://doi.org/10.1007/s00259-021-05492-z
Romeo, V., Moy, L., & Pinker, K. (2023). AI-enhanced PET and MR imaging for patients with breast cancer. PET Clinics, 18(4), 567–575. https://doi.org/10.1016/j.cpet.2023.05.002
Roy, A., & Bera, S. (2016). CAF cellular glycolysis: Linking cancer cells with the microenvironment. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 37(7), 8503–8514. https://doi.org/10.1007/s13277-016-5049-3
Sarhangi, N., Hajjari, S., Heydari, S. F., Ganjizadeh, M., Rouhollah, F., & Hasanzad, M. (2022). Breast cancer in the era of precision medicine. Molecular Biology Reports, 49(10), 10023–10037. https://doi.org/10.1007/s11033-022-07571-2
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7–33. https://doi.org/10.3322/caac.21708
Stanzione, A., Cuocolo, R., Ugga, L., Verde, F., Romeo, V., Brunetti, A., & Maurea, S. (2022). Oncologic imaging and radiomics: A walkthrough review of methodological challenges. Cancers, 14(19), Article 4871. https://doi.org/10.3390/cancers14194871
Stringer-Reasor, E. M., Elkhanany, A., Khoury, K., Simon, M. A., & Newman, L. A. (2021). Disparities in breast cancer associated with African American identity. American Society of Clinical Oncology Educational Book, 41, e29-e46. https://doi.org/10.1200/EDBK_319929
Tsang, J. Y. S., & Tse, G. M. (2020). Molecular classification of breast cancer. Advances in Anatomic Pathology, 27(1), 27-35. https://doi.org/10.1097/PAP.0000000000000232
Valente, S., & Roesch, E. (2024). Breast cancer survivorship. Journal of Surgical Oncology, 130(1), 8-15. https://doi.org/10.1002/jso.27627
Vander Heiden, M. G., & DeBerardinis, R. J. (2017). Understanding the intersections between metabolism and cancer biology. Cell, 168(4), 657-669. https://doi.org/10.1016/j.cell.2016.12.039
Vasan, N., Toska, E., & Scaltriti, M. (2019). Overview of the relevance of PI3K pathway in HR-positive breast cancer. Annals of Oncology, 30(Suppl_10), x3-x11. https://doi.org/10.1093/annonc/mdz281
Vieira, A. F., & Schmitt, F. (2018). An update on breast cancer multigene prognostic tests-emergent clinical biomarkers. Frontiers in Medicine, 5, Article 248. https://doi.org/10.3389/fmed.2018.00248
Vuong, D., Simpson, P. T., Green, B., Cummings, M. C., & Lakhani, S. R. (2014). Molecular classification of breast cancer. Virchows Archiv, 465(1), 1-14. https://doi.org/10.1007/s00428-014-1593-7
Wang, C., Kar, S., Lai, X., Cai, W., Arfuso, F., Sethi, G., Lobie, P. E., Goh, B. C., Lim, L. H. K., Hartman, M., Chan, C. W., Lee, S. C., Tan, S. H., & Kumar, A. P. (2018). Triple negative breast cancer in Asia: An insider's view. Cancer Treatment Reviews, 62, 29-38. https://doi.org/10.1016/j.ctrv.2017.10.014
Wang, Z., Zhang, X., Shen, P., Loggie, B. W., Chang, Y., & Deuel, T. F. (2006). A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proceedings of the National Academy of Sciences of the United States of America, 103(24), 9063-9068. https://doi.org/10.1073/pnas.0603339103
Weigelt, B., Geyer, F. C., & Reis-Filho, J. S. (2010). Histological types of breast cancer: How special are they? Molecular Oncology, 4(3), 192-208. https://doi.org/10.1016/j.molonc.2010.04.004
Weigelt, B., Kreike, B., & Reis-Filho, J. S. (2009). Metaplastic breast carcinomas are basal-like breast cancers: A genomic profiling analysis. Breast Cancer Research and Treatment, 117(2), 273-280. https://doi.org/10.1007/s10549-008-0197-9
Witowski, J., Heacock, L., Reig, B., Kang, S. K., Lewin, A., Pysarenko, K., Patel, S., Samreen, N., Rudnicki, W., Łuczyńska, E., Popiela, T., Moy, L., & Geras, K. J. (2022). Improving breast cancer diagnostics with deep learning for MRI. Science Translational Medicine, 14(664), eabo4802. https://doi.org/10.1126/scitranslmed.abo4802
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020). Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research, 22(1), Article 61. https://doi.org/10.1186/s13058-020-01296-5
Zardavas, D., Te Marvelde, L., Milne, R. L., Fumagalli, D., Fountzilas, G., Kotoula, V., Razis, E., Papaxoinis, G., Joensuu, H., Moynahan, M. E., Hennessy, B. T., Bieche, I., Saal, L. H., Stal, O., Iacopetta, B., Jensen, J. D., O'Toole, S., Lopez-Knowles, E., Barbaraeschi, M., … Loi, S. (2018). Tumor PIK3CA genotype and prognosis in early-stage breast cancer: A pooled analysis of individual patient data. Journal of Clinical Oncology, 36(10), 981-990. https://doi.org/10.1200/JCO.2017.74.8301
Zhang, W., Guan, X., & Tang, J. (2021). The long non-coding RNA landscape in triple-negative breast cancer. Cell Proliferation, 54(2), e12966. https://doi.org/10.1111/cpr.12966
Zhang, X. (2023). Molecular classification of breast cancer: Relevance and challenges. Archives of Pathology and Laboratory Medicine, 147(1), 46-51. https://doi.org/10.5858/arpa.2022-0070-RA
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Imam Malik Kabir
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
&
